DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
A continuous glucose monitor turns the black box of metabolic response into data. Here is how glucose tracking helps on semaglutide and tirzepatide, what targets to aim for, and whether non-diabetics benefit.
GLP-1s slow gastric emptying and enhance glucose-dependent insulin secretion. On a CGM, this shows up as flatter post-meal peaks, fewer sharp spikes, and a tighter time-in-range band. As your appetite drops and meals shrink, the glucose curve typically smooths within the first few weeks. Tirzepatide’s added GIP activity tends to produce even flatter curves than semaglutide in many users.
Non-diabetic reference ranges. Diabetics: follow your endocrinologist’s individualized targets.
If you take insulin or a sulfonylurea with a GLP-1, the combination increases hypoglycemia risk. A CGM with low-glucose alerts can warn you before symptoms appear, especially overnight. This is the single strongest reason for diabetic GLP-1 users to wear a CGM during titration.
Editorial summary, not medical advice. Glucose targets are general references; your prescriber sets individualized goals. CGM use for non-diabetics is for metabolic insight, not diagnosis.